{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:01:06Z","timestamp":1778904066828,"version":"3.51.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032441","name":"Immunic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007827","name":"American College of Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastrointestinal Endoscopy Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.giec.2024.11.001","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:47:13Z","timestamp":1751590033000},"page":"803-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drugs in Development and Clinical Trials for Celiac Disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Adam C.","family":"Bledsoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Therrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.giec.2024.11.001_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1080\/00365521.2016.1218540","article-title":"Long-term mucosal recovery and healing in celiac disease is the rule - not the exception","volume":"51","author":"Haere","year":"2016","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.giec.2024.11.001_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2016.11.004","article-title":"No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease","volume":"152","author":"Murray","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2024.11.001_bib3","article-title":"Real-world gluten exposure in patients with celiac disease on gluten-free diets, determined from gliadin immunogenic peptides in urine and fecal samples","author":"Stefanolo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.giec.2024.11.001_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ajcn\/nqaa188","article-title":"Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease","author":"Ruiz-Carnicer","year":"2020","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.giec.2024.11.001_bib5","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2019.12.016","article-title":"Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten","volume":"158","author":"Silvester","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.giec.2024.11.001_bib6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/gutjnl-2023-329751","article-title":"Persistent villous atrophy predicts development of complications and mortality in adult patients with coeliac disease: a multicentre longitudinal cohort study and development of a score to identify high-risk patients","volume":"72","author":"Schiepatti","year":"2023","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.giec.2024.11.001_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.14309\/ajg.0000000000001139","article-title":"Persistent villous atrophy in de novo adult patients with celiac disease and strict control of gluten-free diet adherence: a multicenter prospective study (CADER study)","volume":"116","author":"Fernandez-Banares","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"13","key":"10.1016\/j.giec.2024.11.001_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/nu14132776","article-title":"Non-responsive and refractory coeliac disease: experience from the NHS england national centre","volume":"14","author":"Penny","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib9","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/ctg.2016.70","article-title":"Outcome of referrals for non-responsive celiac disease in a tertiary center: low incidence of refractory celiac disease in The Netherlands","volume":"8","author":"van Wanrooij","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"13","key":"10.1016\/j.giec.2024.11.001_bib10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3748\/wjg.v27.i13.1311","article-title":"Non-responsive celiac disease in children on a gluten free diet","volume":"27","author":"Veeraraghavan","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib11","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s10620-018-4936-4","article-title":"Hypervigilance to a gluten-free diet and decreased quality of life in teenagers and adults with celiac disease","volume":"63","author":"Wolf","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib12","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s10620-023-07912-6","article-title":"Maladaptive food attitudes and behaviors in individuals with celiac disease and their association with quality of life","volume":"68","author":"Gholmie","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.14309\/ajg.0000000000001778","article-title":"Survey-based study on food insecurity during COVID-19 for households with children on a prescribed gluten-free diet","volume":"117","author":"Du","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.giec.2024.11.001_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MCG.0000000000001646","article-title":"Food insecurity negatively impacts gluten avoidance and nutritional intake in patients with celiac disease","volume":"56","author":"Ma","year":"2022","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1210\/jc.2013-3164","article-title":"Persistent mucosal damage and risk of fracture in celiac disease","volume":"99","author":"Lebwohl","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-159-3-201308060-00006","article-title":"Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study","volume":"159","author":"Lebwohl","year":"2013","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.giec.2024.11.001_bib17","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1053\/j.gastro.2020.07.007","article-title":"Risk of small bowel adenocarcinoma, adenomas, and carcinoids in a nationwide cohort of individuals with celiac disease","volume":"159","author":"Emilsson","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.13725","article-title":"Symptomatic suspected gluten exposure is common among patients with coeliac disease on a gluten-free diet","volume":"44","author":"Silvester","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.giec.2024.11.001_bib19","author":"Celiac"},{"key":"10.1016\/j.giec.2024.11.001_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-91316-2","article-title":"Global prevalence of celiac disease: systematic review and meta-analysis","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1038\/s41598-021-82023-8","article-title":"Prevalence of celiac disease in low and high risk population in Asia-Pacific region: a systematic review and meta-analysis","volume":"11","author":"Ashtari","year":"2021","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.giec.2024.11.001_bib22","first-page":"S3","article-title":"Review article: epidemiology of coeliac disease","volume":"56","author":"Makharia","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.giec.2024.11.001_bib23","article-title":"Less hidden celiac disease but increased gluten avoidance without a diagnosis in the United States: findings from the national health and nutrition examination surveys from 2009 to 2014","author":"Choung","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.giec.2024.11.001_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cgh.2016.04.032","article-title":"Ethnic variations in duodenal villous atrophy consistent with celiac disease in the United States","volume":"14","author":"Krigel","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.giec.2024.11.001_bib25","unstructured":"U.S. Food and Drug Administration . Guidance for industry: collection of race and ethnicity data in clinical trials. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical (Accessed 19 November 2024)."},{"key":"10.1016\/j.giec.2024.11.001_bib26","unstructured":"U.S. Food and Drug Administration . Guidance for industry: collection of race and ethnicity data in clinical trials. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial (Accessed 19 November 2024)."},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2016.07.025","article-title":"Development of celiac disease therapeutics: report of the third gastroenterology regulatory endpoints and advancement of therapeutics workshop","volume":"151","author":"Leffler","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2024.11.001_bib28","unstructured":"Gastroenterology regulatory endpoints and the advancement of therapeutics VI (GREAT VI) workshop on celiac disease. 2021. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/gastroenterology-regulatory-endpoints-and-advancement-therapeutics-vi-great-vi-workshop-celiac (Accessed 19 November 2024)."},{"key":"10.1016\/j.giec.2024.11.001_bib29","unstructured":"Celiac disease: developing drugs for adjunctive treatment to a gluten-free diet. 2022. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/celiac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet (Accessed 19 November 2024)."},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.gastro.2022.06.086","article-title":"Regulatory and clinical expert perspective of the 2022 FDA draft guidance \"celiac disease: developing drugs for adjunctive treatment to a gluten-free diet\"","volume":"164","author":"Goldkind","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2022.07.024","article-title":"FDA draft guidance for developing drugs for adjunctive treatment to a gluten-free diet: comments by the society for the study of celiac disease","volume":"164","author":"Council","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2023.08.051","article-title":"Standardizing randomized controlled trials in celiac disease: an international multidisciplinary appropriateness study","volume":"166","author":"Lebwohl","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.giec.2024.11.001_bib34","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"Lahdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib35","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2022.07.071","article-title":"Latiglutenase protects the mucosa and attenuates symptom severity in patients with celiac disease exposed to a gluten challenge","volume":"163","author":"Murray","year":"2022","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib36","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease","volume":"146","author":"Lahdeaho","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.giec.2024.11.001_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","volume":"8","author":"Murray","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","article-title":"Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study","volume":"37","author":"Kelly","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.giec.2024.11.001_bib40","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","article-title":"A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge","volume":"107","author":"Leffler","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/apt.15551","article-title":"Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease","volume":"51","author":"Daveson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ajcn\/nqx049","article-title":"Determination of gluten consumption in celiac disease patients on a gluten-free diet","volume":"107","author":"Syage","year":"2018","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14309\/ajg.0000000000002075","article-title":"American College of gastroenterology guidelines update: diagnosis and management of celiac disease","volume":"118","author":"Rubio-Tapia","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1053\/j.gastro.2020.10.040","article-title":"Evaluating responses to gluten challenge: a randomized, double-blind, 2-dose gluten challenge trial","volume":"160","author":"Leonard","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2024.11.001_bib45","unstructured":"Khater S, Assaf A, Perez-Cuadrado Robles E, et al., Predictive factors for long-term complications of celiac disease: a large retrospective study from the celac network. Presented at: 19th international celiac disease symposium, 19-22, 2022; October, 2022."},{"issue":"5","key":"10.1016\/j.giec.2024.11.001_bib46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(22)00428-9","article-title":"Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study","volume":"8","author":"Tye-Din","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s12276-024-01179-1","article-title":"Intestinal stem cells: guardians of homeostasis in health and aging amid environmental challenges","volume":"56","author":"Choi","year":"2024","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ygh2.380","article-title":"Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet","volume":"2","author":"Daveson","year":"2020","journal-title":"GastroHep"},{"issue":"10","key":"10.1016\/j.giec.2024.11.001_bib49","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41551-019-0424-1","article-title":"Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes","volume":"3","author":"Wilson","year":"2019","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"10.1016\/j.giec.2024.11.001_bib50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2858","article-title":"Antigen-presenting cell function in the tolerogenic liver environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","article-title":"Harnessing nanoparticles for immune modulation","volume":"36","author":"Getts","year":"2015","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib52","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib53","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2015.01.006","article-title":"Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice","volume":"62","author":"Carambia","year":"2015","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.giec.2024.11.001_bib54","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/jf205319s","article-title":"In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix","volume":"60","author":"Gujral","year":"2012","journal-title":"J Agric Food Chem"},{"issue":"5","key":"10.1016\/j.giec.2024.11.001_bib55","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","article-title":"AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease","volume":"62","author":"Sample","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.gastro.2008.09.016","article-title":"Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium","volume":"136","author":"Pinier","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2011.10.038","article-title":"The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues","volume":"142","author":"Pinier","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.giec.2024.11.001_bib58","doi-asserted-by":"crossref","first-page":"e109972","DOI":"10.1371\/journal.pone.0109972","article-title":"BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity","volume":"9","author":"McCarville","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.giec.2024.11.001_bib59","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00034.2006","article-title":"Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease","volume":"291","author":"Stepniak","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"11","key":"10.1016\/j.giec.2024.11.001_bib60","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3748\/wjg.v30.i11.1545","article-title":"Effect of Aspergillus Niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet","volume":"30","author":"Stefanolo","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","article-title":"The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo","volume":"134","author":"Tye-Din","year":"2010","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10620-011-1906-5","article-title":"Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials","volume":"57","author":"Siegel","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.giec.2024.11.001_bib63","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s10620-017-4687-7","article-title":"Latiglutenase improves symptoms in seropositive celiac disease patients while on a gluten-free diet","volume":"62","author":"Syage","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"40","key":"10.1016\/j.giec.2024.11.001_bib64","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/jacs.5b08325","article-title":"Engineering of Kuma030: a gliadin peptidase that rapidly degrades immunogenic gliadin peptides in gastric conditions","volume":"137","author":"Wolf","year":"2015","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2024.11.001_bib66","doi-asserted-by":"crossref","unstructured":"Burianek F, Probstl D, Peelen E, et al., First in human trial of IMU-856, an orally available epigenetic modulator of barrier regeneration for the treatment of celiac disease. Presented at, Digestive Disease Week, 2024. May 18-21, 2024.","DOI":"10.1016\/S0016-5085(24)00939-9"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.peptides.2012.02.015","article-title":"Larazotide acetate regulates epithelial tight junctions in vitro and in vivo","volume":"35","author":"Gopalakrishnan","year":"2012","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib68","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","article-title":"Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial","volume":"148","author":"Leffler","year":"2015","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.giec.2024.11.001_bib69","doi-asserted-by":"crossref","first-page":"e24092","DOI":"10.1371\/journal.pone.0024092","article-title":"Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection","volume":"6","author":"McSorley","year":"2011","journal-title":"PLoS One"},{"issue":"3\u20134","key":"10.1016\/j.giec.2024.11.001_bib70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijpara.2012.12.005","article-title":"Changed gluten immunity in celiac disease by Necator americanus provides new insights into autoimmunity","volume":"43","author":"Croese","year":"2013","journal-title":"Int J Parasitol"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","article-title":"Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease","volume":"135","author":"Croese","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib72","doi-asserted-by":"crossref","first-page":"e17366","DOI":"10.1371\/journal.pone.0017366","article-title":"Effect of hookworm infection on wheat challenge in celiac disease--a randomised double-blinded placebo controlled trial","volume":"6","author":"Daveson","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.giec.2024.11.001_bib73","doi-asserted-by":"crossref","first-page":"e00274","DOI":"10.14309\/ctg.0000000000000274","article-title":"Randomized, placebo controlled trial of experimental hookworm infection for improving gluten tolerance in celiac disease","volume":"11","author":"Croese","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"7796","key":"10.1016\/j.giec.2024.11.001_bib74","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","article-title":"IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease","volume":"578","author":"Abadie","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.giec.2024.11.001_bib75","doi-asserted-by":"crossref","first-page":"113560","DOI":"10.1016\/j.ab.2019.113560","article-title":"Substrates, inhibitors, and probes of mammalian transglutaminase 2","volume":"591","author":"Zhuang","year":"2020","journal-title":"Anal Biochem"},{"issue":"10","key":"10.1016\/j.giec.2024.11.001_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cells11101667","article-title":"Features of ZED1227: the first-in-class tissue transglutaminase inhibitor undergoing clinical evaluation for the treatment of celiac disease","volume":"11","author":"Buchold","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.giec.2024.11.001_bib77","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/j.1460-2075.1990.tb08211.x","article-title":"Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor","volume":"9","author":"Mallett","year":"1990","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.giec.2024.11.001_bib78","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.4049\/jimmunol.161.12.6510","article-title":"Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses","volume":"161","author":"Gramaglia","year":"1998","journal-title":"J Immunol"},{"issue":"3\u20134","key":"10.1016\/j.giec.2024.11.001_bib79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cytogfr.2008.04.003","article-title":"Immune regulation and control of regulatory T cells by OX40 and 4-1BB","volume":"19","author":"So","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib80","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1084\/jem.180.2.757","article-title":"Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor","volume":"180","author":"Godfrey","year":"1994","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.giec.2024.11.001_bib81","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/1074-7613(95)90031-4","article-title":"Cross-linking of OX40 ligand, a member of the TNF\/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells","volume":"2","author":"Stuber","year":"1995","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.giec.2024.11.001_bib82","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1349-7006.2001.tb01105.x","article-title":"Expression of gp34 (OX40 ligand) and OX40 on human T cell clones","volume":"92","author":"Takasawa","year":"2001","journal-title":"Jpn J Cancer Res"},{"issue":"10","key":"10.1016\/j.giec.2024.11.001_bib83","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.4049\/jimmunol.176.10.5975","article-title":"OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity","volume":"176","author":"Soroosh","year":"2006","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib84","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1046\/j.1365-2362.2000.00658.x","article-title":"The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis)","volume":"30","author":"Stuber","year":"2000","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cgh.2010.04.009","article-title":"Celiac crisis is a rare but serious complication of celiac disease in adults","volume":"8","author":"Jamma","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib86","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ajg.2017.71","article-title":"Open-capsule budesonide for refractory celiac disease","volume":"112","author":"Mukewar","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib87","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s10620-020-06454-5","article-title":"Enteric-release budesonide may Be useful in the management of non-responsive celiac disease","volume":"66","author":"Therrien","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.gtc.2018.09.010","article-title":"Refractory celiac disease","volume":"48","author":"Malamut","year":"2019","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib89","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1007\/s10620-024-08436-3","article-title":"Budesonide induces favourable histologic and symptomatic recovery in patients with non-responsive and refractory coeliac disease when given in an open capsule format","volume":"69","author":"Saitta","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib90","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cgh.2019.03.029","article-title":"Efficacy of enteric-release oral budesonide in treatment of acute reactions to gluten in patients with celiac disease","volume":"18","author":"Therrien","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.giec.2024.11.001_bib91","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1038\/s41467-023-44083-4","article-title":"Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease","volume":"14","author":"Okura","year":"2023","journal-title":"Nat Commun"},{"issue":"62","key":"10.1016\/j.giec.2024.11.001_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg4925","article-title":"A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation","volume":"6","author":"Frick","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.giec.2024.11.001_bib93","doi-asserted-by":"crossref","first-page":"110259","DOI":"10.1016\/j.clim.2024.110259","article-title":"A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease","volume":"264","author":"Hardy","year":"2024","journal-title":"Clin Immunol"},{"issue":"490","key":"10.1016\/j.giec.2024.11.001_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5563","article-title":"Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects","volume":"11","author":"Klotz","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.giec.2024.11.001_bib95","unstructured":"Risnes LF, Brottveit M, Robertsen I, et al. Teriflunomide as immunotherapy for celiac disease \u2013 results from a double-blinded, Randomized phase 2A STUDY presented at: United European Gastroenterology Week; 2023."},{"issue":"4","key":"10.1016\/j.giec.2024.11.001_bib96","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2013.12.023","article-title":"Interleukin 15 and CD4(+) T cells cooperate to promote small intestinal enteropathy in response to dietary antigen","volume":"146","author":"Korneychuk","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib97","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","article-title":"Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis","volume":"9","author":"Vicari","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.giec.2024.11.001_bib98","doi-asserted-by":"crossref","unstructured":"Schumann M, Houbiers JG, Chvatchko Y, et al., CALY-002, an ANTI-IL-15 antibody, prevents gluten challengeinduced mucosal damage and inflammation: results from a phase 1A\/B study. Presented at, Digestive Disease Week, 2024. May 18-21, 2024.","DOI":"10.1016\/S0016-5085(24)00940-5"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib99","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.gastro.2019.10.006","article-title":"Identification of a gammac receptor antagonist that prevents reprogramming of human tissue-resident cytotoxic T cells by IL15 and IL21","volume":"158","author":"Ciszewski","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.giec.2024.11.001_bib100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.giec.2024.11.001_bib101","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2012-08-450585","article-title":"Phase 1 trial of IL-15 trans presentation blockade using humanized Mikbeta1 mAb in patients with T-cell large granular lymphocytic leukemia","volume":"121","author":"Waldmann","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.giec.2024.11.001_bib102","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.giec.2024.11.001_bib103","unstructured":"Khater S, Lhermitte L, Bruneau J, et al. Long-term follow-up of patients with type 2 refractory celiac disease treated with amg 714, an anti-interleukin 15 monoclonal antibody, at georges pompidou hospital. Presented at: United European Gastroenterology Week; 2022. May 18-21, 2024, Washington DC, USA."},{"key":"10.1016\/j.giec.2024.11.001_bib104","doi-asserted-by":"crossref","unstructured":"Schnir V, Rigby M, Calota MR, et al. Developing TEV-53408 for the treatment of celiac disease: summary of preliminary results from the first in human phase 1 study in healthy volunteers. Presented at: Digestive Disease Week; 2024; Session Su1326. May 18-21, 2024, Washington DC, USA.","DOI":"10.1016\/S0016-5085(24)02155-3"},{"issue":"2","key":"10.1016\/j.giec.2024.11.001_bib105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.giec.2024.11.001_bib106","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"10.1016\/j.giec.2024.11.001_bib107","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.giec.2024.11.001_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.05.022","article-title":"Enduring clinical remission in refractory celiac disease type II with tofacitinib: an open-label clinical study","author":"Dieckman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.giec.2024.11.001_bib109","first-page":"472","article-title":"GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease","volume":"13","author":"Eksteen","year":"2010","journal-title":"Idrugs"},{"issue":"10","key":"10.1016\/j.giec.2024.11.001_bib110","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.giec.2024.11.001_bib111","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","article-title":"PTG-100, an oral alpha4beta7 antagonist peptide: preclinical development and phase 1 and 2a studies in ulcerative colitis","volume":"161","author":"Sandborn","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Gastrointestinal Endoscopy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052515724001089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052515724001089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:59:58Z","timestamp":1761433198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052515724001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1052515724001089"],"URL":"https:\/\/doi.org\/10.1016\/j.giec.2024.11.001","relation":{},"ISSN":["1052-5157"],"issn-type":[{"value":"1052-5157","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs in Development and Clinical Trials for Celiac Disease","name":"articletitle","label":"Article Title"},{"value":"Gastrointestinal Endoscopy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.giec.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}